[go: up one dir, main page]

WO2012064159A3 - 항암용 조성물 - Google Patents

항암용 조성물 Download PDF

Info

Publication number
WO2012064159A3
WO2012064159A3 PCT/KR2011/008645 KR2011008645W WO2012064159A3 WO 2012064159 A3 WO2012064159 A3 WO 2012064159A3 KR 2011008645 W KR2011008645 W KR 2011008645W WO 2012064159 A3 WO2012064159 A3 WO 2012064159A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutically acceptable
acceptable salt
anticancer composition
anticancer
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2011/008645
Other languages
English (en)
French (fr)
Other versions
WO2012064159A2 (ko
Inventor
서성은
김선화
박유진
양혜영
김은지
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NOAHM Inc
Original Assignee
NOAHM Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NOAHM Inc filed Critical NOAHM Inc
Publication of WO2012064159A2 publication Critical patent/WO2012064159A2/ko
Publication of WO2012064159A3 publication Critical patent/WO2012064159A3/ko
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

본 발명은 5-하이드록시메틸푸르푸랄(5-hydroxymethylfurfural) 또는 이의 약학적으로 허용가능한 염, 메트포민(Metformin) 또는 이의 약학적으로 허용가능한 염, 및 구연산(Citric acid) 또는 이의 약학적으로 허용가능한 염으로 구성된 군으로부터 선택되는 2종 이상의 화합물을 유효성분으로 포함하는 항암용 조성물 또는 암의 예방 또는 개선을 위한 식품 조성물, 상기 항암용 조성물을 개체에 투여하여 암을 예방 또는 치료하는 방법, 및 상기 2종 이상의 화합물의 용도에 관한 것이다. 본 발명의 항암용 조성물은 5-하이드록시메틸푸르푸랄, 메트포민 및 구연산의 상승적 조합 제제로서 각각의 단일제제보다 적은 양으로 암세포의 생존을 억제할 수 있으며, 정상세포에는 독성을 나타내지 않으면서 암세포의 세포주기를 선택적으로 억제하여, 이의 사멸을 유도할 수 있으므로, 부작용 없는 항암제로 유용하게 사용할 수 있다.
PCT/KR2011/008645 2010-11-11 2011-11-11 항암용 조성물 Ceased WO2012064159A2 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20100112345 2010-11-11
KR10-2010-0112345 2010-11-11

Publications (2)

Publication Number Publication Date
WO2012064159A2 WO2012064159A2 (ko) 2012-05-18
WO2012064159A3 true WO2012064159A3 (ko) 2012-07-19

Family

ID=46051460

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/008645 Ceased WO2012064159A2 (ko) 2010-11-11 2011-11-11 항암용 조성물

Country Status (2)

Country Link
KR (1) KR101377037B1 (ko)
WO (1) WO2012064159A2 (ko)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101458061B1 (ko) * 2012-08-24 2014-11-05 서성은 항암용 조성물
WO2014083095A1 (en) * 2012-11-29 2014-06-05 Universitaet Basel Combinations of metformin with other compounds for the treatment of cancer and for immunosuppression
CA2896587C (en) * 2013-01-04 2019-02-05 Board Of Regents, The University Of Texas System Compositions comprising citrate and applications thereof
DE102013106530A1 (de) * 2013-06-21 2014-12-24 Christoph Pallua Krebsmedikament
CN109692171A (zh) * 2017-10-22 2019-04-30 海南医学院 一种治疗肝癌化合物
KR102760589B1 (ko) 2022-07-26 2025-01-24 국립목포대학교산학협력단 5-하이드록시메틸 푸르푸랄을 포함하는 대동맥 판막 협착증 예방 또는 치료용 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030075124A (ko) * 2002-03-16 2003-09-22 배석년 구연산, 알부민 및 아연을 함유한 항암 조성물
US20050274391A1 (en) * 2002-05-17 2005-12-15 Karl Groke Means for weaning people off smoking and alcohol
US20080194019A1 (en) * 2003-09-09 2008-08-14 Beth Israel Deaconess Medical Center, Inc. Tumor Suppressor Lkb1 Kinase Directly Activates Amp-Activated Kinase

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030075124A (ko) * 2002-03-16 2003-09-22 배석년 구연산, 알부민 및 아연을 함유한 항암 조성물
US20050274391A1 (en) * 2002-05-17 2005-12-15 Karl Groke Means for weaning people off smoking and alcohol
US20080194019A1 (en) * 2003-09-09 2008-08-14 Beth Israel Deaconess Medical Center, Inc. Tumor Suppressor Lkb1 Kinase Directly Activates Amp-Activated Kinase

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PAMELA J. GOODWIN ET AL.: "Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anticancer agents", BREAST CANCER RES TREAT, vol. 126, 26 October 2010 (2010-10-26), pages 215 - 220 *

Also Published As

Publication number Publication date
WO2012064159A2 (ko) 2012-05-18
KR20120050919A (ko) 2012-05-21
KR101377037B1 (ko) 2014-03-21

Similar Documents

Publication Publication Date Title
WO2013019058A3 (en) Pharmaceutical composition for inhibiting cancer recurrence or metastasis
WO2009152189A8 (en) Low dose topiramate/phentermine compostion and methods of use thereof
WO2013066839A3 (en) Compounds and methods
WO2013066835A3 (en) Compounds and methods
WO2012034055A3 (en) Compounds as c-met kinase inhibitors
WO2012064159A3 (ko) 항암용 조성물
WO2012143576A3 (en) Compounds for preventing, reducing and/or alleviating itchy skin condition(s)
MY197785A (en) Combinations of lsd1 inhibitors for the treatment of hematological malignancies
EA201300556A1 (ru) Аминоспиртзамещенные производные 2,3-дигидроимидазо[1,2-с] хиназолина, пригодные для лечения гиперпролиферативных нарушений и заболеваний, связанных с ангиогенезом
EA201391315A1 (ru) Гуанидиновое соединение
CA2818925A1 (en) Inhibitors of the activity of complex iii of the mitochondrial electron transport chain and use thereof for treating diseases
WO2011118976A3 (en) Pharmaceutical composition for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same
WO2014040052A3 (en) Glycyrrhetinic acid derivatives with anti-inflammatory activity
WO2011159100A3 (ko) 항암 활성을 나타내는 약제학적 조성물
WO2010087565A3 (ko) 피페린의 신규한 용도
RU2018135973A (ru) Фармацевтическая комбинация, содержащая метроформин и дигидрокверценин, и ее применение для лечения рака
WO2011049327A3 (en) A skin external composition comprising a salt and sugar as active ingredients for preventing and treating vaginosis and the use thereof
WO2010041832A3 (ko) 패 유래 화합물 함유 항산화 활성 조성물
RU2014129508A (ru) Новая комбинация
WO2012161497A3 (ko) 보습능이 우수한 펩타이드 유도체 및 이의 용도
ZA201500362B (en) Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient
IN2014DN01619A (ko)
PH12013500371A1 (en) Therapeutic agent for pain
WO2012112232A8 (en) METHODS AND COMPOSITIONS FOR TREATING β-THALASSEMIA AND SICKLE CELL DISEASE
WO2012053768A3 (en) Aryloxyphenoxyacetyl-based compound having hif-1 inhibition activity, preparation method thereof and pharmaceutical composition containing the same as an active ingredient

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11840513

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11840513

Country of ref document: EP

Kind code of ref document: A2